Table 3.
Adverse events and dropout rate reported by 41 studies.
| Author (year) | Dropout rate | Adverse events |
|---|---|---|
| Reginster 200117 | 34% (n = 73) | 83 and 101 individuals reported adverse events in GS and placebo group, respectively. No difference was found between treatment and placebo group |
| Appelboom 200118 | 13% (n = 35) | 28, 24 and 23 individuals reported adverse events in ASU low dose, ASU high dose and placebo group, respectively. No difference was found between treatment and placebo group |
| Jung 200119 | 3% (n = 3) | 5, 6, 3 and 5 individuals reported adverse events in SKI 306X low dose, SKI 306X medium dose, SKI 306X high dose and placebo group, respectively. No difference was found between treatment and placebo group |
| Schmid 200120 | 0 | 16 and 16 individuals reported adverse events in Willow bark extract and placebo group, respectively. No difference was found between treatment and placebo group |
| Colker 200221 | 22% (n = 9) | Adverse events have been supervised. No safety problems were recognized |
| Zenk 200222 | 17% (n = 7) | 14, 14 and 14 individuals reported adverse events in MPC, GS and placebo group, respectively. No long-term adverse events of any treatment were reported. No difference was found between treatment and placebo group |
| Lequense 200223 | 41% (n = 67) | 39 and 39 individuals reported adverse events in ASU and placebo group, respectively. No difference was found between treatment and placebo group |
| McAlindon 200424 | 9% (n = 19) | 18 and 14 individuals reported adverse events in GS and placebo group, respectively. No difference was found between treatment and placebo group |
| Miller 200525 | 15% (n = 16) | Adverse events have been supervised. No serious safety problems were recognized |
| Kim 200626 | 20% (n = 10) | 21 and 19 individuals reported adverse events in MSM and placebo group, respectively. No difference was found between treatment and placebo group |
| Pavelka 200727 | 9% (n = 16) | 36 and 24 individuals reported adverse events in Diacerein and placebo group, respectively. No statistically significant difference was found between treatment and placebo group |
| Farid 200728 | 5% (n = 2) | Adverse events have been supervised. No safety problems were recognized |
| Mehta 200729 | 17% (n = 16) | 4 and 3 individuals reported adverse events in GS and Reparagen group, respectively. No statistically significant difference was found between ASU groups and the placebo |
| Alishiri GH.H. 200730 | 4% (n = 5) | Not report |
| Sengupta 20088 | 7% (n = 5) | 24, 23 and 23 individuals reported adverse events in 5-Loxin 100, 5-Loxin 250 mg/day and placebo group, respectively. No difference was found between treatment and placebo group |
| Kalman 2008 31 | 20% (n = 4) | 1 and 2 individuals reported adverse events in Chicken comb extract and placebo group, respectively. No statistically significant difference was found between treatment and placebo group |
| Frestedt 200832 | 28% (n = 20) | 12, 12, 13 and 140 individuals reported adverse events in Aquamin, GS, GS + Aquamin and placebo group, respectively. No statistically significant difference was found between treatment groups and placebo group |
| Jacquet 200933 | 6% (n = 5) | 14 and 13 individuals reported adverse events in Phytalgic and placebo group, respectively. No statistically significant difference was found between treatment and placebo group. No statistically significant difference was found between treatment groups and placebo group |
| Frestedt 200934 | 36% (n = 8) | 8 and 14 individuals reported adverse events in Aquamin and placebo group, respectively |
| Ruff 200935 | 37% (n = 22) | Adverse events have been supervised. No safety problems were recognized |
| Farid 201036 | 17% (n = 7) | Adverse events have been supervised. No safety problems were recognized |
| Sengupta 201037 | 5% (n = 3) | 0, 1 and 1 individuals reported adverse events in 5 -Loxin, Aflapin and placebo group, respectively. No statistically significant difference was found between treatment groups and placebo group |
| Debbi 201138 | 0 | Adverse events have been supervised. No safety problems were recognized |
| Notarnicola 201139 | 0 | Adverse events have been supervised. No safety problems were recognized |
| Schauss 201240 | 15% (n = 12) | 3 and 6 individuals reported adverse events in BioCell Collagen and placebo group, respectively. There was no significant difference between the two groups in the total number of adverse events |
| McAlindon 201341 | 15% (n = 22) | 31 and 23 individuals reported adverse events in Cholecalciferol and placebo group, respectively. There was no significant difference between the two groups in the total number of adverse events |
| Ebrahimi 201442 | 13% (n = 12) | Adverse events have been supervised. No safety problems were recognized |
| Kolahi 201543 | 4% (n = 3) | Adverse events have been supervised. No safety problems were recognized |
| Kumar 201544 | 7% (n = 2) | 1 and 0 individuals reported adverse events in PCP and placebo group, respectively. There was no significant difference between the two groups in the total number of adverse events |
| Dehghan 201545 | 8% (n = 7) | Not reported |
| Jin 201646 | 0 | 56 and 37 individuals reported adverse events in Vitamin D3 and placebo group, respectively |
| Stebbings 201647 | 19% (n = 8) | 6, 9 and 7 individuals reported adverse events in ART low dose, ART high dose and placebo group, respectively |
| Lugo 201648 | 12% (n = 22) | 8, 28 and 9 individuals reported adverse events in UC-II, GC and placebo group, respectively |
| Lubis 201749 | 0 | Not reported |
| Rafarf 201750 | 9% (n = 6) | Not reported |
| Lei 201751 | 6% (n = 28) | Adverse events have been supervised. No safety problems were recognized |
| Shin 201852 | 17% (n = 10) | Not reported |
| Dehghani 201853 | 5% (n = 4) | Not reported |
| Salimzadeh 201854 | 5% (n = 4) | Not reported |
| Hancke 201955 | 5% (n = 5) | 8, 1 and 2 individuals reported adverse events in ParActin low dose, ParActin high dose and placebo group, respectively. There was no significant difference between the ParActin groups and the placebo in the total number of adverse events |
| Majeed 201956 | 12% (n = 6) | Adverse events have been supervised. No safety problems were recognized |
| Rondanelli 201957 | 0 | Adverse events have been supervised. No safety problems were recognized |
ART Artemisia annua extract, ASU Avocado soybean unsaponifiable, DBE Deer bone extract, GC Glucosamine hydrochloride + chondroitin sulfate, GS Glucosamine sulphate, MSM Methylsulfonylmethane, PCP Collagen peptides isolated from pork skin, UC-II Undenatured collagen type II.